OrphAI Therapeutics

Executive Summary

OrphAI Therapeutics is a private, AI-driven biotechnology company based in Cambridge, MA, focused on discovering and developing novel small molecule therapies for pulmonary hypertension (PH), Bronchiolitis Obliterans Syndrome (BOS) post-lung transplant, and oncology. Founded in 2020, the company leverages its proprietary AI platform to identify and optimize drug candidates across these indications. While specific pipeline details are limited, OrphAI's approach targets significant unmet medical needs, particularly in rare and orphan diseases where conventional drug development has been challenging. The company's early-stage pipeline and reliance on AI-based discovery position it as a potential innovator in precision medicine, but the lack of publicly disclosed clinical data and funding information introduces uncertainty.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead PH Candidate70% success
• H1 2027Phase 1 Data Readout for Oncology Program60% success
• Q3 2026Series A or B Financing Announcement50% success